Stockreport

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Silverback Therapeutics, Inc.  (SBTX) 
PDF SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology pl [Read more]